Forum Discussions

These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders.  The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.

Each forum will be 60 minutes moderated discuss​ion with maximum 3 minutes introduction statement from each participant followed by questions from the audience submitted via Ask the Speaker function in the mobile APP and introduced to the discussion by the moderator. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.

Then followed by the session:

FORUM DISCUSSION 1: APPLICATIONS OF NEUROPSYCHOLOGY, PET, MRI, EEG, AND CSF FOR DIAGNOSIS AND ASSESSMENT OF TREATMENT EFFECTS

02 April 2020
16:30 – 17:30, Hall E

Moderators: Henrik Zetterberg, Sweden; Angela Genge, Canada
Discussants:
T. Babic, Austria
J. Beaver, USA
T. Bittner, Switzerland
A. Nordberg, Sweden
G. Rabinovici, USA

 

FORUM DISCUSSION 2: TRANSLATIONAL DRUG DISCOVERY IN PD/ LBD PHASE I-III

03 April 2020
14:30 – 15:30, Hall E

Moderators: Jamie Eberling, USA; Walter Koroshetz, USA
Discussants:
D. Aarsland, Norway
B. Mollenhauer,Germany
T. Ferguson, USA
F. Stocchi, Italy

FORUM DISCUSSION 3: TRANSLATIONAL DRUG DISCOVERY IN AD: LEARNING FROM FAILURES AND SUCCESSES

03 April 2020
14:30 – 15:30, Hall E

Moderators: Rudolph Tanzi, USA; Ezio Giacobini, Switzerland
Discussants:
R. Bateman, USA
S. Budd-Haeberlein, USA

G. Gold, Switzerland
L. Kulic, Switzerland
E. Masliah, USA